Ticagrelor orodispersible tablets + Ticagrelor standard tablets
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ST Elevation Myocardial Infarction
Conditions
ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Trial Timeline
Jun 27, 2019 → Aug 31, 2020
NCT ID
NCT03822377About Ticagrelor orodispersible tablets + Ticagrelor standard tablets
Ticagrelor orodispersible tablets + Ticagrelor standard tablets is a phase 3 stage product being developed by AstraZeneca for ST Elevation Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT03822377. Target conditions include ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03822377 | Phase 3 | Completed |
Competing Products
8 competing products in ST Elevation Myocardial Infarction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Butylphthalide + Butylphthalide placebo | CSPC Pharmaceutical Group Limited | Phase 3 | 76 |
| Tirofiban + Ticagrelor | AstraZeneca | Phase 3 | 77 |
| Ticagrelor | AstraZeneca | Phase 2 | 52 |
| Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd) | AstraZeneca | Approved | 85 |
| ticagrelor + clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Evolocumab 140 MG/ML + Standard of care (SOC) | Amgen | Approved | 84 |
| dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) | Shenzhen Salubris Pharmaceuticals | Pre-clinical | 22 |